Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis
Biotech
Lilly drops program against NASH target that caught Pfizer's eye
Fifteen months after dropping its first candidate, Lilly has kicked the second KHK inhibitor program from its phase 1 pipeline.
Nick Paul Taylor
Feb 2, 2023 8:45am
Viking accuses Chinese biotech of 'ruse' to raid trade secrets
Jan 3, 2023 6:30am
Novartis seeks partners for asthma, eye disease and NASH assets
Jul 19, 2022 8:35am
Novo Nordisk, Echosens team up on NASH diagnosis tech
Jun 24, 2022 12:24pm
